What is ADCT's health score?

ADC Therapeutics SA (ADCT) has a TradeApes health score of 38 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is ADCT's estimated fair value?

Based on our 5-year discounted cash flow model, ADC Therapeutics SA's estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is ADCT undervalued or overvalued?

Our model currently rates ADCT as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for ADCT... Refresh in a moment for the full analysis.

ADC Therapeutics SA (ADCT)

Healthcare Inconclusive inconclusive weak

$1.35

Updated: 2026-06-04

TradeApes Score

Financial Strength

25 Stressed

Operating Trend

40 Weak

Relative Value

60 Healthy

Capital Allocation

20 Stressed

Risk

35 Weak

Key Findings

+ Historically cheap — EV/EBITDA in bottom 25% of its 5-year range

Unlock Full Report →

− Weak interest coverage — earnings barely cover debt service

Unlock Full Report →

Create an account for unlimited access

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.